2HA Stock Overview A clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Spero Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Spero Therapeutics Historical stock prices Current Share Price US$0.99 52 Week High US$1.75 52 Week Low US$0.89 Beta 0.61 1 Month Change -6.34% 3 Month Change -13.25% 1 Year Change -25.86% 3 Year Change -92.39% 5 Year Change -87.87% Change since IPO -90.25%
Recent News & Updates
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023) Nov 17
Investor sentiment improves as stock rises 17% Nov 05
Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results Oct 30
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy Oct 03
New major risk - Revenue and earnings growth Aug 06
Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023) Aug 06 See more updates
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.061 loss in 3Q 2023) Nov 17
Investor sentiment improves as stock rises 17% Nov 05
Spero Therapeutics, Inc. Announces SPR720 Phase 2a Interim Results Oct 30
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy Oct 03
New major risk - Revenue and earnings growth Aug 06
Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.23 loss in 2Q 2023) Aug 06
Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 30
New major risk - Revenue and earnings growth Jun 07
First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.25 loss in 1Q 2023) May 17
Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024 Mar 30
New major risk - Revenue and earnings growth Mar 18 Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Mar 16
Full year 2023 earnings released: EPS: US$0.43 (vs US$1.24 loss in FY 2022) Mar 14
Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 07
New minor risk - Profitability Feb 26
Co-Founder & Chairman of the Board recently sold €81k worth of stock Feb 07
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections Jan 02
Forecast to breakeven in 2026 Dec 31
New minor risk - Shareholder dilution Nov 17
Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.33 loss in 3Q 2022) Nov 15
Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 07 Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer
Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023 Sep 02
New major risk - Shareholder dilution Aug 14
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.87 loss in 2Q 2022) Aug 11
Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04 Spero Therapeutics, Inc. Announces Chief Financial Officer Changes
First quarter 2023 earnings released: US$0.25 loss per share (vs US$1.01 loss in 1Q 2022) May 15
Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 06
Full year 2022 earnings released: US$1.24 loss per share (vs US$2.91 loss in FY 2021) Mar 31
Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023 Feb 02
Insufficient new directors Dec 14
Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.70 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16 Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc Nov 10
Spero Therapeutics to Present Data at IDWeek 2022 Oct 20 Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc Sep 23
Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer Sep 16
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration Sep 07
Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.63 loss in 2Q 2021) Aug 12
Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022 Aug 06
The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit Jun 30
Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application Jun 29
Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc May 27
First quarter 2022 earnings released: US$1.01 loss per share (vs US$0.66 loss in 1Q 2021) May 17 Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022 May 10
No longer forecast to breakeven May 05
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline May 04
Insufficient new directors May 02
Full year 2021 earnings released: US$2.91 loss per share (vs US$3.52 loss in FY 2020) Apr 02
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206 Feb 17
Spero Therapeutics Receives Up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients Jan 20
Spero Therapeutics, Inc. Announces Lifting of FDA Clinical Trial Hold on SPR720 Jan 05
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis Jan 04
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.86 loss in 3Q 2020) Nov 11
Insufficient new directors Sep 04
Forecast to breakeven in 2023 Aug 07
Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.85 loss in 2Q 2020) Aug 06
Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc. Jul 02
Spero Therapeutics, Inc. Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of Spr206 Jun 16
Spero Therapeutics, Inc. Wins Funding of $2.09 Million, with the Potential for Up to an Additional $21.3 Million over 5 Years, from the National Institute of Allergy and Infectious Diseases May 18
First quarter 2021 earnings released: US$0.66 loss per share (vs US$1.22 loss in 1Q 2020) May 09
Full year 2020 earnings released: US$3.52 loss per share (vs US$3.36 loss in FY 2019) Mar 13
Revenue misses expectations Mar 13
New 90-day high: €19.00 Feb 10
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial Feb 06
Spero Therapeutics Announces Issuance of Allowance for A U.S. Patent Covering Lead Candidate Tebipenem HBr Jan 22
Everest Medicines Announces Amended Agreement with Spero Therapeutics Jan 19
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer, Effective as of January 4, 2021 Dec 19
Spero Therapeutics, Inc. Announces First Patient Dosed with SPR720 in Phase 2A Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease Dec 11
New 90-day high: €14.60 Dec 10
Spero Therapeutics, Inc. Appoints Tamara Joseph as Chief Legal Officer Dec 03
New 90-day high: €12.30 Nov 12
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.86 loss per share Nov 07
Spero Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day high: €12.00 Oct 13
Spero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $47.85 million. Sep 12
New 90-day low - €9.00 Aug 28
First half earnings released Aug 07
New 90-day low - €9.85 Aug 03 Shareholder Returns 2HA DE Biotechs DE Market 7D 6.8% 4.0% 0.7% 1Y -25.9% -10.2% 8.4%
See full shareholder returns
Return vs Market: 2HA underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 2HA's price volatile compared to industry and market? 2HA volatility 2HA Average Weekly Movement 9.0% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2HA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2HA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Show more Spero Therapeutics, Inc. Fundamentals Summary How do Spero Therapeutics's earnings and revenue compare to its market cap? 2HA fundamental statistics Market cap €54.72m Earnings (TTM ) €3.42m Revenue (TTM ) €103.73m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2HA income statement (TTM ) Revenue US$106.46m Cost of Revenue US$51.56m Gross Profit US$54.90m Other Expenses US$51.39m Earnings US$3.51m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:29 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Spero Therapeutics, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Esther Lannie Hong Berenberg Jason Matthew Gerberry BofA Global Research Louise Chen Cantor Fitzgerald & Co.
Show 7 more analysts 
